theobromine has been researched along with Obesity in 11 studies
Theobromine: 3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9)
theobromine : A dimethylxanthine having the two methyl groups located at positions 3 and 7. A purine alkaloid derived from the cacao plant, it is found in chocolate, as well as in a number of other foods, and is a vasodilator, diuretic and heart stimulator.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized, double-blind crossover study, 44 apparently healthy overweight (N = 30) and obese (N = 14) men and women with low HDL-C concentrations, consumed daily 500 mg theobromine or placebo for 4 weeks." | 9.30 | Theobromine consumption does not improve fasting and postprandial vascular function in overweight and obese subjects. ( Joris, PJ; Mensink, RP; Plat, J; Smolders, L; van den Driessche, JJ, 2019) |
| "Theobromine alleviated diet-induced obesity in mice by browning of iWAT and activating BAT." | 7.96 | Theobromine alleviates diet-induced obesity in mice via phosphodiesterase-4 inhibition. ( Choi, MJ; Jang, MH; Kang, NH; Mukherjee, S; Pham, HG; Yun, JW, 2020) |
| "Theobromine reduces adipogenesis and proinflammatory cytokines; these data suggest its potential therapeutic effect for treating obesity by control of macrophages infiltration in adipose tissue and inflammation." | 7.91 | Inflammatory Microenvironment and Adipogenic Differentiation in Obesity: The Inhibitory Effect of Theobromine in a Model of Human Obesity In Vitro. ( Bonmassar, E; Fuggetta, MP; Ravagnan, G; Villivà, C; Zonfrillo, M, 2019) |
| "In a randomized, double-blind crossover study, 44 apparently healthy overweight (N = 30) and obese (N = 14) men and women with low HDL-C concentrations, consumed daily 500 mg theobromine or placebo for 4 weeks." | 5.30 | Theobromine consumption does not improve fasting and postprandial vascular function in overweight and obese subjects. ( Joris, PJ; Mensink, RP; Plat, J; Smolders, L; van den Driessche, JJ, 2019) |
| "Theobromine reduces adipogenesis and proinflammatory cytokines; these data suggest its potential therapeutic effect for treating obesity by control of macrophages infiltration in adipose tissue and inflammation." | 3.91 | Inflammatory Microenvironment and Adipogenic Differentiation in Obesity: The Inhibitory Effect of Theobromine in a Model of Human Obesity In Vitro. ( Bonmassar, E; Fuggetta, MP; Ravagnan, G; Villivà, C; Zonfrillo, M, 2019) |
| "Body weight reductions were 0." | 2.70 | Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. ( Andersen, T; Fogh, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Jang, MH | 1 |
| Mukherjee, S | 1 |
| Choi, MJ | 1 |
| Kang, NH | 1 |
| Pham, HG | 1 |
| Yun, JW | 1 |
| Smolders, L | 1 |
| Mensink, RP | 1 |
| van den Driessche, JJ | 1 |
| Joris, PJ | 1 |
| Plat, J | 1 |
| Fuggetta, MP | 1 |
| Zonfrillo, M | 1 |
| Villivà, C | 1 |
| Bonmassar, E | 1 |
| Ravagnan, G | 1 |
| Kim, J | 2 |
| Shim, J | 1 |
| Lee, CY | 1 |
| Lee, KW | 1 |
| Lee, HJ | 1 |
| Grandner, MA | 1 |
| Jackson, N | 1 |
| Gerstner, JR | 1 |
| Knutson, KL | 1 |
| HECKENBACH, W | 1 |
| Boozer, CN | 1 |
| Nasser, JA | 1 |
| Heymsfield, SB | 1 |
| Wang, V | 1 |
| Chen, G | 1 |
| Solomon, JL | 1 |
| Andersen, T | 1 |
| Fogh, J | 1 |
| Dembowski, U | 1 |
| Marx-Heep, I | 1 |
| Adams, HJ | 1 |
| Dulloo, AG | 1 |
| Seydoux, J | 1 |
| Girardier, L | 1 |
| Bittiner, SB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Short-term Theobromine Supplementation on Vascular Function and Intestinal apoA-I Production in Fasting and in the Postprandial State[NCT02209025] | 48 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for theobromine and Obesity
| Article | Year |
|---|---|
Cocoa phytochemicals: recent advances in molecular mechanisms on health.
Topics: Animals; Biological Availability; Cacao; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Flavo | 2014 |
3 trials available for theobromine and Obesity
| Article | Year |
|---|---|
Theobromine consumption does not improve fasting and postprandial vascular function in overweight and obese subjects.
Topics: Aged; Blood Pressure; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Fasting; Femal | 2019 |
An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial.
Topics: Adult; Anthropometry; Blood Pressure; Caffeine; Dietary Supplements; Double-Blind Method; Drug Combi | 2001 |
Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients.
Topics: Caffeine; Double-Blind Method; Female; Gastric Emptying; Humans; Ilex paraguariensis; Male; Obesity; | 2001 |
7 other studies available for theobromine and Obesity
| Article | Year |
|---|---|
Theobromine alleviates diet-induced obesity in mice via phosphodiesterase-4 inhibition.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cyclic Nucleotide Phosphodiesterases, Type 4; | 2020 |
Inflammatory Microenvironment and Adipogenic Differentiation in Obesity: The Inhibitory Effect of Theobromine in a Model of Human Obesity In Vitro.
Topics: Adipocytes; Adipogenesis; Cell Cycle; Cell Differentiation; Cell Line; Cell Line, Tumor; Cytokines; | 2019 |
Dietary nutrients associated with short and long sleep duration. Data from a nationally representative sample.
Topics: Adult; Aged; Alcohol Drinking; Antioxidants; Diet; Dietary Carbohydrates; Drinking; Energy Intake; E | 2013 |
[Eupond in obesity].
Topics: Atropine; Bile Acids and Salts; Choline; Cycloheptanes; Drug Combinations; Inulin; Obesity; Plants; | 1955 |
[Angioneuropathies, angiolopathies and other disorders of blood circulation. Treatment in ambulatory patients].
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Obes | 1979 |
Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition?
Topics: Adenosine; Adipose Tissue, Brown; Animals; Caffeine; Diet; Dose-Response Relationship, Drug; Drug Sy | 1992 |
Oxpentifylline treatment of venous leg ulcers.
Topics: Humans; Leg Ulcer; Obesity; Pentoxifylline; Theobromine | 1990 |